A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board

被引：21

作者：

Kuruvilla, John ^{[1
,2
]}

Assouline, Sarit ^{[3
,4
]}

Hodgson, David ^{[1
,2
]}

MacDonald, David ^{[5
,6
]}

Stewart, Doug ^{[7
,8
,9
]}

Christofides, Anna ^{[10
]}

Komolova, Marina ^{[10
]}

Connors, Joseph ^{[11
,12
]}

机构：

[1] Univ Toronto, Dept Med Oncol, Toronto, ON, Canada

[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[3] McGill Univ, Dept Oncol, Montreal, PQ, Canada

[4] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada

[5] Dalhousie Univ, Div Hematol, Halifax, NS, Canada

[6] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[7] Univ Calgary, Dept Oncol, Calgary, AB, Canada

[8] Univ Calgary, Dept Med, Calgary, AB, Canada

[9] Tom Baker Canc Clin, Calgary, AB, Canada

[10] New Evidence, Toronto, ON, Canada

[11] Univ British Columbia, Div Med Oncol, Vancouver, BC V5Z 1M9, Canada

[12] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2015年 / 15卷 / 02期

关键词：

Canadian; Follicular lymphoma; Guidelines; Hematology; Indolent lymphoma; Lymphoma; NON-HODGKINS-LYMPHOMA; STAGE-I-III; BENDAMUSTINE PLUS RITUXIMAB; TERM-FOLLOW-UP; FONDAZIONE ITALIANA LINFOMI; RANDOMIZED CONTROLLED-TRIAL; PROGRESSION-FREE SURVIVAL; MANTLE-CELL LYMPHOMAS; INDOLENT B-CELL; PHASE-III;

D O I：

10.1016/j.clml.2014.07.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL) in North America. Because of the heterogeneity of the disease, treatment options vary from observation to aggressive therapies or stem cell transplantation, or both. Although advances in treatment have improved outcomes, the disease remains largely incurable. In Canada, no unified national guideline exists for the front-line treatment of FL; provincial guidelines vary and are largely based on funding. There is therefore a need for evidence-based national treatment guidelines that are supported by Canadian hematologists to ensure that patients with FL have equitable access to the best available care. A group of experts from across Canada developed a national evidence-based treatment guideline to provide health care professionals with clear guidance on the first-line management of FL. Results of a systematic review of the literature are presented with consensus recommendations based on available evidence.

引用

页码：59 / 74

页数：16

共 50 条

[41] The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy [J].

Kimby, Eva ;

Lockmer, Sandra ;

Holte, Harald ;

Hagberg, Hans ;

Wahlin, Bjorn E. ;

Brown, Peter ;

Ostenstad, Bjorn .

BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (05) :738-747

[42] Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study [J].

Cartron, Guillaume ;

Bachy, Emmanuel ;

Tilly, Herve ;

Daguindau, Nicolas ;

Pica, Gian-Matteo ;

Bijou, Fontanet ;

Mounier, Christiane ;

Clavert, Aline ;

Damaj, Gandhi Laurent ;

Slama, Borhane ;

Casasnovas, Olivier ;

Houot, Roch ;

Bouabdallah, Krimo ;

Sibon, David ;

Fitoussi, Olivier ;

Morineau, Nadine ;

Herbaux, Charles ;

Gastinne, Thomas ;

Fornecker, Luc-Matthieu ;

Haioun, Corinne ;

Launay, Vincent ;

Araujo, Carla ;

Benbrahim, Omar ;

Sanhes, Laurence ;

Gressin, Remy ;

Gonzalez, Hugo ;

Morschhauser, Franck ;

Ternant, David ;

Xerri, Luc ;

Tarte, Karin ;

Pranger, Delphine .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (19) :3523-+

[43] 90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial [J].

Scholz, Christian W. ;

Pinto, Antonello ;

Linkesch, Werner ;

Linden, Ola ;

Viardot, Andreas ;

Keller, Ulrich ;

Hess, Georg ;

Lastoria, Secondo ;

Lerch, Kristina ;

Frigeri, Ferdinando ;

Arcamone, Manuela ;

Stroux, Andrea ;

Frericks, Bernd ;

Pott, Christiane ;

Pezzutto, Antonio .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (03) :308-313

[44] Phase III study of watchful waiting vs. rituximab as first-line treatment in advanced stage follicular lymphoma with low tumour burden (JCOG1411, FLORA study) [J].

Miyamoto, Kenichi ;

Fukuhara, Noriko ;

Maruyama, Dai ;

Shibata, Taro ;

Nakamura, Kenichi ;

Ishizawa, Kenichi ;

Tsukasaki, Kunihiro ;

Nagai, Hirokazu .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (08) :777-780

[45] Pathologic Validation of Deauville Score-Based Disease on F-18 FDG PET/CT after First-Line Treatment in Patients with Lymphoma [J].

Kumar, Rajender ;

Krishnaraju, Venkata Subramanian ;

Mittal, Bhagwant Rai ;

Shankar, Kritin ;

Singh, Harmandeep ;

Ramachandran, Arivan ;

Bhattacharya, Anish ;

Prakash, Gaurav ;

Bal, Amanjit ;

Malhotra, Pankaj .

NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 58 (06) :332-340

[46] Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2 [J].

Liu, Shu ;

Huang, He ;

Chen, Rong-xin ;

Wang, Zhao ;

Guan, Yan-ping ;

Peng, Chen ;

Fang, Xiao-jie ;

Chen, Zhuo-jia ;

Guan, Shao-xing ;

Zhu, Xia ;

Ren, Quan-guang ;

Yao, Yu-yi ;

Huang, Hong-bing ;

Huang, Min ;

Wang, Xue-ding ;

Lin, Tong-yu .

ACTA PHARMACOLOGICA SINICA, 2021, 42 (04) :641-647

[47] Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2 [J].

Shu Liu ;

He Huang ;

Rong-xin Chen ;

Zhao Wang ;

Yan-ping Guan ;

Chen Peng ;

Xiao-jie Fang ;

Zhuo-jia Chen ;

Shao-xing Guan ;

Xia Zhu ;

Quan-guang Ren ;

Yu-yi Yao ;

Hong-bing Huang ;

Min Huang ;

Xue-ding Wang ;

Tong-yu Lin .

Acta Pharmacologica Sinica, 2021, 42 :641-647

[48] Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study [J].

Mondello, Patrizia ;

Steiner, Normann ;

Willenbacher, Wolfgang ;

Wasle, Ines ;

Zaja, Francesco ;

Zambello, Renato ;

Visentin, Andrea ;

Mauro, Endri ;

Ferrero, Simone ;

Ghione, Paola ;

Pitini, Vincenzo ;

Cuzzocrea, Salvatore ;

Mian, Michael .

ANNALS OF HEMATOLOGY, 2016, 95 (07) :1107-1114

[49] Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study [J].

Patrizia Mondello ;

Normann Steiner ;

Wolfgang Willenbacher ;

Ines Wasle ;

Francesco Zaja ;

Renato Zambello ;

Andrea Visentin ;

Endri Mauro ;

Simone Ferrero ;

Paola Ghione ;

Vincenzo Pitini ;

Salvatore Cuzzocrea ;

Michael Mian .

Annals of Hematology, 2016, 95 :1107-1114

[50] Efficacy and safety of rituximab biosimilars or reference product as first-line treatment in patients with low-tumour-burden follicular lymphoma: A systematic review and meta-analysis [J].

Yang, Liu ;

Zheng, Zhiwei ;

Li, Na ;

Zheng, Bin ;

Liu, Maobai ;

Cai, Hongfu .

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (12) :1923-1931

← 1 2 3 4 5 →